Thinking
laterally
about CAR-T
Our mission is to develop next generation CAR-T therapies using the Company’s proprietary Lateral CAR platform to improve treatment outcomes and save the lives of patients with refractory cancers
Latest News
'Next-generation CAR T cells'
Dr John Maher responds to questions about how to overcome the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours and how the work as Leucid Bio is making strides towards this goal.
Leucid CSO, Dr John Maher, will present data on our allogeneic platform at the 2nd Allogeneic Cell Therapies Summit, Europe
30th January-1st February 2023
London
Our Science
CAR T-cell therapy is a revolutionary technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.
Lateral CAR T-Cell Platform
Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
.png)
T4 Immunotherapy
Leucid Bio’s T4 Immunotherapy is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.
Novel Manufacturing Platforms
Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.
_2.jpg)
Our Science
CAR T-cell therapy is a revolutionary technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.
Lateral CAR T-Cell Platform
Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
T2, allogeneic gd T-cell platform
Leucid has developed a patented technique for generating gd T-cells from the peripheral blood of healthy donors, we call T2. T2 cells are a distinct population of gd T-cells and ideally suited for off-the-shelf cellular therapy.
T4 Immunotherapy
Leucid Bio’s T4 Immunotherapy (LEU001) is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.
Novel Manufacturing Platforms
Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.